

GRIFOLS

Grifols advances on its strategic investment from GIC with 90% of consents from its notes holders and lenders

- Grifols closes the "Consent Solicitation" from Notes holders and lenders in record time.
- The company has received consent from the 87.93% of Secured Notes holders, the 81.01% of Unsecured Notes holders, 93.82% of lenders under the Credit Agreement and the EIB in order to allow Grifols' corporate reorganization that will make possible the investment from GIC, the sovereign wealth fund of Singapore.
- GIC will invest USD 1 billion to acquire a minority stake in Grifols' wholly owned subsidiary Biomat USA, which manages 296 U.S.-based plasma centers.

Barcelona (Spain), August 16, 2021.- Grifols (MCE:GRF, MCE:GRF.P, NASDAQ:GRFS) announces that it has closed the "Consent Solicitation" from holders of Senior Notes and lenders receiving 90% of consents. It will allow an internal corporate reorganization which will make possible the investment from GIC, the sovereign wealth fund of Singapore, as a strategic and long-term investor.

The consents received, following the announcement of the process on July 30, 2021, far exceed the requisite consents with respect to the Secured Notes, Unsecured Notes and other lenders, including banks and institutional investors.

Specifically, Grifols has received consents from 87.93% of its Senior Secured Notes holders of the aggregate principal amount of its 1,472,889,000 euros (voting as a single class and including EUR 905,000,000 1.625% Senior Secured Notes due 2025 and EUR 770,000,000 2.250% Senior Secured Notes due 2027); from 81.01% or EUR 810,110,000,000 of holders of the aggregate principal amount of its EUR 1,000,000,000 at 3.200% Senior Unsecured Notes due 2025; and 93.82% of the banks and institutional investors, including lenders under the Credit Agreement, as well as from the European Investment Bank (EIB).

Alfredo Arroyo, CFO says, *"the high percentage of consents received shows the large degree of confidence of main bondholders and lenders in our long-term and sustainable business model, as well as in our commitment to reduce our leverage ratios while continuing bringing added-value opportunities, as proven by our strategic agreement with GIC"*.

GRIFOLS

About the strategic investment from GIC in Biomat

After closing the consent solicitation, Grifols advances to the definitive agreement entered with GIC, under which the sovereign wealth fund of Singapore, will invest USD 990 million in Biomat USA Inc. (“Biomat”), a Grifols’ wholly-owned US subsidiary which manages 296 plasma centers throughout the United States.

In exchange, GIC will receive an aggregate of 10 Class B common shares of Biomat and 9 Class B common shares of a newly-established sub-holding company. These common shares will represent directly and indirectly an aggregate of 23.8% of the equity of Biomat.

As part of the transaction, GIC will become a strategic and long-term investor in Grifols’ business, holding a minority stake in Biomat through the acquisition of newly issued non-voting stock.

Grifols will continue to oversee all aspects of Biomat’s management and operations. All plasma collected by Biomat and its subsidiaries will continue to be supplied to Grifols for the production of plasma-derived medicines, through a long-term plasma supply agreement.

Grifols will apply all proceeds from GIC’s investment to repay debt as part of its ongoing commitment to reduce its financial leverage ratio.

The closing of GIC’s strategic investment in Grifols is subject to certain conditions, including applicable regulatory authorizations, such as the Committee on Foreign Investment in the United States (CFIUS).

Grifols retained Osborne Clarke, S.L.P and Proskauer Rose, L.L.P as legal advisors for the transaction, and Nomura Securities International, Inc. as sole financial advisor. GIC retained Dechert LLP as legal advisor.

Investor contact:

Investor Relations and Sustainability

inversores@grifols.com - investors@grifols.com

sostenibilidad@grifols.com - sustainability@grifols.com

Tel. +34 93 571 02 21

Media contacts:

Raquel Lumbreras

Raquel_lumbreras@duomocomunicacion.com

Borja Gómez

Borja_gomez@duomocomunicacion.com

Duomo Comunicación – **Grifols Press Office**

Tel. +34 91 311 92 89 - 91 311 92 90

+34 659 57 21 85 / +34 650 40 22 25

Grifols

Media Press Office

media@grifols.com

Tel. +34 571 00 02

GRIFOLS

About Grifols

Grifols is a global healthcare company founded in Barcelona in 1909 committed to improving the health and well-being of people around the world. Its four divisions – Bioscience, Diagnostic, Hospital and Bio Supplies – develop, produce and market innovative solutions and services that are sold in more than 100 countries.

Pioneers in the plasma industry, Grifols operates a growing network of donation centers worldwide. It transforms collected plasma into essential medicines to treat rare, chronic and, at times, life-threatening conditions. As a recognized leader in transfusion medicine, Grifols also offers a comprehensive portfolio of solutions designed to enhance safety from donation to transfusion. In addition, the company supplies tools, information and services that enable hospitals, pharmacies and healthcare professionals to efficiently deliver expert medical care.

Grifols, with close to 24,000 employees in 30 countries, is committed to a sustainable business model that sets the standard for continuous innovation, quality, safety and ethical leadership.

In 2020, Grifols' economic impact in its core countries of operation was EUR 7.5 billion. The company also generated 140,000 jobs, including indirect and induced jobs.

The company's class A shares are listed on the Spanish Stock Exchange, where they are part of the Ibex-35 (MCE:GRF). Grifols non-voting class B shares are listed on the Mercado Continuo (MCE:GRF.P) and on the U.S. NASDAQ through ADRs (NASDAQ:GRFS).



For more information about Grifols, please visit www.grifols.com

LEGAL DISCLAIMER

The facts and figures contained in this report that do not refer to historical data are “future projections and assumptions”. Words and expressions such as “believe”, “hope”, “anticipate”, “predict”, “expect”, “intend”, “should”, “will seek to achieve”, “it is estimated”, “future” and similar expressions, in so far as they relate to the Grifols group, are used to identify future projections and assumptions. These expressions reflect the assumptions, hypotheses, expectations and predictions of the management team at the time of writing this report, and these are subject to a number of factors that mean that the actual results may be materially different. The future results of the Grifols group could be affected by events relating to its own activities, such as a shortage of supplies of raw materials for the manufacture of its products, the appearance of competitor products on the market, or changes to the regulatory framework of the markets in which it operates, among others. At the date of compiling this report, the Grifols group has adopted the necessary measures to mitigate the potential impact of these events. Grifols, S.A. does not accept any obligation to publicly report, revise or update future projections or assumptions to adapt them to events or circumstances subsequent to the date of writing this report, except where expressly required by the applicable legislation. This document does not constitute an offer or invitation to buy or subscribe shares in accordance with the provisions of the following Spanish legislation: Royal Legislative Decree 4/2015, of 23 October, approving recast text of Securities Market Law; Royal Decree Law 5/2005, of 11 March and/or Royal Decree 1310/2005, of 4 November, and any regulations developing this legislation. In addition, this document does not constitute an offer of purchase, sale or exchange, or a request for an offer of purchase, sale or exchange of securities, or a request for any vote or approval in any other jurisdiction. The information included in this document has not been verified nor reviewed by the external auditors of the Grifols group.